Jeffrey Cummings

, MD, ScD

Professor of Brain Science, Director of Chambers-Gundy Center for Transformative Neuroscience, Co-Director of Pam Quirk Brain Health and Biomarker Laboratory, University of Nevada, Las Vegas

Jeffrey Cummings, MD, ScD, is the JoyChambers-Grundy Professor of Brain Science, Director of the Chambers-GundyCenter for Transformative Neuroscience, and Co-Director of the Pam Quirk BrainHealth and Biomarker Laboratory, Department of Brain Health, School ofIntegrated Health Sciences, University of Nevada Las Vegas (UNLV). Dr. Cummingsis globally known for his contributions to Alzheimer’s research, drugdevelopment, and clinical trials. He has been recognized for his research andleadership contributions in the field of Alzheimer’s disease through manyawards including the Ronald and Nancy Reagan Research Award of the nationalAlzheimer’s Association (2008), Lifetime Achievement Award of the Society forBehavioral and Cognitive Neurology (2017), Distinguished Scientist Award of theAmerican Association of Geriatric Psychiatry (2010), Bengt Winblad LifetimeAchievement Award from the national Alzheimer’s Association (2019), and theAlzheimer’s Drug Discovery Foundation’s Melvin R. Goodes Prize. He was featuredin Gentleman’s Quarterly (June 2009) as a “Rock Star of Science™.” Dr.Cummings completed Neurology residency and a Fellowship in Behavioral Neurologyat Boston University, followed by a Research Fellowship in Neuropathology andNeuropsychiatry at the National Hospital for Nervous Diseases, Queen Square,London. Dr. Cummings was formerly Director of the Mary S. Easton Center forAlzheimer’s Disease Research at UCLA, and Director of the Cleveland Clinic LouRuvo Center for Brain Health. Dr. Cummings’s interests embrace clinical trials,developing new therapies for brain diseases, and the interface of neuroscienceand society. He has authored or edited 43 books and published over 800peer-reviewed papers.

Read more

This Speaker's Sessions

Wednesday Oct. 18
1:30–2:15 PM
Watch Replay
Now Live!

Meeting Patient Demand for Alzheimer's Treatment

Treatment of Alzheimer’s continues to improve with a more patient-centered approach, as new drugs give doctors more options for their patients. Ideally, a patient sees their primary care physician, raises a concern about cognition, has the concern validated, and is given a referral to a physician with the skill, experience, and infrastructure to consider this patient for a new Alzheimer’s therapy. Key Question: What do physicians and patients need to know to navigate this brave new world so the patient gets the right drug and in time to make a difference?

View SessionWatch Replay